- 期刊
- OpenAccess
Safety and Efficacy of Vinorelbine in the Treatment of Non-Small Cell Lung Cancer
並列摘要
Lung cancer remains the most frequently diagnosed cancer in the United States, excluding non-melanoma skin cancer. Non-small cell lung cancer (NSCLC) constitutes the majority (more than 80%) of lung cancer diagnoses. Systemic therapy, with either cytotoxic chemotherapy and/or targeted therapies, has been established to provide benefit to patients with NSCLC in both the adjuvant and advanced disease settings. Vinorelbine, a semi-synthetic vinca-alkaloid has been extensively tested alone and in combination with other cytotoxic or targeted agents in the treatment of NSCLC. Its safety has been well established with neutropenia, anemia, nausea, and vomiting being the most frequently encountered toxicities. The data defining the risks and benefits of vinorelbine in the treatment of NSCLC will be summarized.
延伸閱讀
- Binder, D., & Hegenbarth, K. (2013). Emerging Options for the Management of Non-Small Cell Lung Cancer. Clinical Medicine Insights: Oncology, (), 221-234. https://doi.org/10.4137/CMO.S10269
- Karim, N. A., Bui, H., Pathrose, P., Starnes, S., Patil, N., Shehata, M., Mostafa, A., Rao, M., Zarzour, A., & Anderson, M. (2014). The Use of Pharmacogenomics for Selection of Therapy in Non-Small-Cell Lung Cancer. Clinical Medicine Insights: Oncology, (), 139-144. https://doi.org/10.4137/CMO.S18369
- Chiu, S. C., Chang, K. H., Chen, Y. J., Chung, C. H., Lai, Y. L., & Wu, M. H. (1998). The Role of Radiotherapy for Advanced Non-Small Cell Lung Cancer. 放射治療與腫瘤學, 5(4), 277-283. https://doi.org/10.6316/TRO/199805(4)277
- 許南榮（2012）。Study on Prognostic Factors of Early Stage Non-small Cell Lung Cancer〔博士論文，中山醫學大學〕。華藝線上圖書館。https://doi.org/10.6834/CSMU.2012.00048
- Amico, T. A. D. (2007). Molecular Biologic Staging and Selection of Therapy for Non-Small Cell Lung Cancer. Journal of Medical Sciences, 27(1), 1-7. https://doi.org/10.6136/JMS.2007.27(1).001